TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25055497

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Aminomethylbenzoic acid
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid
Number of subjects: 63
Study: 23451439

Group type: EXPERIMENTAL
Intervention: Minimally invasive lateral approach
Number of subjects: 28

Group type: COMPARATOR
Intervention: Mini-midvastus approach
Number of subjects: 28
Study: 19966044

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (online training, guideline dissemination, educational sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (dissemination of guidelines only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 0
Study: 18854916

Group type: EXPERIMENTAL
Intervention: Dysport
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Botox
Number of subjects: 79
Study: 16019927

Group type: EXPERIMENTAL
Intervention: Gamma-ray irradiation (60Co-gamma source)
Number of subjects: 20
Study: 12196659

Group type: EXPERIMENTAL
Intervention: Oral albuterol for 6 months
Number of subjects: 13
Study: 10503860

Group type: EXPERIMENTAL
Intervention: GM-CSF mouthrinse (0.5 microg/mL), administered for 1 minute 3 times per day after oral hygiene procedures, starting from the first day of mucositis until clinical improvement.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (historical patients with similar clinical characteristics).
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: GM-CSF mouthrinse (0.5 microg/mL).
Number of subjects: 39
Study: 9117817

Group type: EXPERIMENTAL
Intervention: Film dressing left intact until suture removal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Existing wound-care protocol of a dry dressing removed after 48 hours
Number of subjects: 30
Study: 1914267

Group type: EXPERIMENTAL
Intervention: 1 tablet of sublingual nitroglycerin without transdermal nitroglycerin (Group 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1 tablet of sublingual nitroglycerin with 12-hour-daily intermittent therapy of transdermal nitroglycerin (Group 2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 1 tablet of sublingual nitroglycerin with continuous therapy of transdermal nitroglycerin (Group 3)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2 tablets of sublingual nitroglycerin with continuous therapy of transdermal nitroglycerin (Group 4)
Number of subjects: 48
Study: 6349375

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 31524642

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy (neoadjuvant)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Combination of TRG and TNM
Number of subjects: 389

Group type: COMPARATOR
Intervention: TNM staging alone
Number of subjects: 389
Study: 30286787

Group type: EXPERIMENTAL
Intervention: Nutritional guidance provided by a registered dietitian once every 3 months for a total of three sessions.
Number of subjects: 250

Group type: COMPARATOR
Intervention: No nutritional guidance (control group).
Number of subjects: 250
Study: 27281260

Group type: EXPERIMENTAL
Intervention: TEAS combined with CBT plus clomipramine (Group A)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: TEAS combined with CBT plus placebo (Group B)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Simulated (placebo) TEAS combined with CBT plus clomipramine (Group C)
Number of subjects: 360
Study: 24980290

Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil (EVOO, 10 g)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Corn oil (10 g)
Number of subjects: 25
Study: 22810985

Group type: EXPERIMENTAL
Intervention: Fortified complementary food (instant flour)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Fortified complementary food (food complement)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Control group (traditional complementary food at home)
Number of subjects: 426
Study: 17497593

Group type: EXPERIMENTAL
Intervention: BCAA drink containing 2 g of BCAA and 0.5 g of Arg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 8
Study: 16377602

Group type: EXPERIMENTAL
Intervention: Single tailored (ST) mailout of print material
Number of subjects: 4014

Group type: EXPERIMENTAL
Intervention: Multiple tailored (MT) mailouts of print materials spanning 12 months
Number of subjects: 4014

Group type: EXPERIMENTAL
Intervention: Multiple retailored (MRT) mailouts spanning 12 months
Number of subjects: 4014

Group type: COMPARATOR
Intervention: Single untailored (SU) mailout of print material
Number of subjects: 4014
Study: 12377400

Group type: EXPERIMENTAL
Intervention: rTMS at individual motor threshold (MT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: rTMS at 90% subthreshold intensity
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham rTMS (low intensity)
Number of subjects: 31
Study: 10413266

Group type: EXPERIMENTAL
Intervention: Prolonged intermittent high‐intensity shuttle running (90 min of intermittent shuttle running and walking)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prolonged intermittent high‐intensity shuttle running
Number of subjects: 16

Group type: COMPARATOR
Intervention: Resting control group
Number of subjects: 16
Study: 7766324

Group type: EXPERIMENTAL
Intervention: Escharectomy during shock stage (Group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Escharectomy after shock stage (Group B)
Number of subjects: 50
Study: 2110386

Group type: EXPERIMENTAL
Intervention: Ifosfamide (8 to 10 g/m2) with mesna uroprotection, bolus administration
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Ifosfamide (8 to 18 g/m2) with mesna uroprotection, continuous infusion
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Ifosfamide (up to 18 g/m2)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Ifosfamide (16 g/m2)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Ifosfamide (18 g/m2)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Ifosfamide with mesna uroprotection
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Ifosfamide
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Ifosfamide without mesna
Number of subjects: 154
Study: 347992

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate intranasal aerosol
Number of subjects: 30
Study: 31759686

Group type: EXPERIMENTAL
Intervention: Cre8 amphilimus eluting stent
Number of subjects: 323

Group type: COMPARATOR
Intervention: Taxus Liberté stent
Number of subjects: 323
Study: 31179799

Group type: EXPERIMENTAL
Intervention: Modified puncture method
Number of subjects: 436

Group type: COMPARATOR
Intervention: Standard infusion puncture method (Control)
Number of subjects: 436
Study: 28591198

Group type: EXPERIMENTAL
Intervention: Single 45mg dose of primaquine (equivalent to three SLD PQ)
Number of subjects: 101

Group type: COMPARATOR
Intervention: DHP-alone (no primaquine)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Single 45mg dose of primaquine
Number of subjects: 101

Group type: COMPARATOR
Intervention: DHP-alone
Number of subjects: 101
Study: 26202995

Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli (1 lozenge containing Lactobacillus reuteri DSM 17938 and ATCC PTA 5289, twice daily for 12 weeks)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo (twice daily for 12 weeks)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 24125608

Group type: EXPERIMENTAL
Intervention: Community-based intervention in Xiacheng and Gongshu districts
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Control area (Xihu district)
Number of subjects: 2016
Study: 21610270

Group type: EXPERIMENTAL
Intervention: Rimonabant
Number of subjects: 661

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study: 19388893

Group type: EXPERIMENTAL
Intervention: Relaxing music
Number of subjects: 372

Group type: COMPARATOR
Intervention: Midazolam (0.05-0.1 mg/kg orally)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Comparison between Relaxing music and Midazolam
Number of subjects: 372
Study: 16455894

Group type: EXPERIMENTAL
Intervention: alpha interferon 2b (IFN-alpha2b) (3 million units three times a week) + ribavirin (800 mg/day)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: pegylated IFN-alpha2b (1.5 mug/kg of body weight/week) + ribavirin (800 mg/day)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: HCV CA below the threshold value (4.18 log(10) pg/ml . 10(4))
Number of subjects: 348
Study: 15320677

Group type: EXPERIMENTAL
Intervention: High-load training
Number of subjects: 26

Group type: COMPARATOR
Intervention: High-repetition training
Number of subjects: 26
Study: 11924291

Group type: EXPERIMENTAL
Intervention: Surgical caps and masks
Number of subjects: 1034

Group type: COMPARATOR
Intervention: No surgical caps and masks (other group)
Number of subjects: 1034
Study: 9613379

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5% twice daily
Number of subjects: 40
Study: 8607321

Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg.kg‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2635342

Group type: EXPERIMENTAL
Intervention: Preliminary mouth wash procedure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sputum preceded spit
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correctly treated patients (80 subjects)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Finding of bacteria in BLA but absent in spit and/or sputum
Number of subjects: 100
Study: 326034

Group type: EXPERIMENTAL
Intervention: Prednisolone therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 27906839

Group type: EXPERIMENTAL
Intervention: Bosentan (500 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 26041745

Group type: EXPERIMENTAL
Intervention: AC→XT (Capecitabine 825 mg/m² twice daily, days 1‐14; Docetaxel 75 mg/m² on day 1)
Number of subjects: 2611

Group type: COMPARATOR
Intervention: AC→T (Doxorubicin and Cyclophosphamide followed by Docetaxel, T dose: 100 mg/m² on day 1)
Number of subjects: 2611

Group type: EXPERIMENTAL
Intervention: AC→XT
Number of subjects: 2611
Study: 23377341

Group type: EXPERIMENTAL
Intervention: Ketoconazole foam, 2%, twice daily
Number of subjects: 500
Study: 22010095

Group type: EXPERIMENTAL
Intervention: Screw-retained restorations
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cemented restorations
Number of subjects: 38
Study: 19801933

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 80
Study: 16714232

Group type: EXPERIMENTAL
Intervention: Phacoemulsification cataract surgery
Number of subjects: 24
Study: 16113459

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (duration: 8 weeks)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (duration: 4 years)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (population: adults with asthma)
Number of subjects: 470
Study: 11497388

Group type: EXPERIMENTAL
Intervention: NK1 receptor antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of NK1 receptor antagonists with existing agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-HT3 receptor antagonists
Number of subjects: 0
Study: 9412749

Group type: EXPERIMENTAL
Intervention: Visual assessment by trained observers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual scoring of skin irritation reactions
Number of subjects: 0
Study: 29324705

Group type: EXPERIMENTAL
Intervention: Chitosan treatment (3200 mg daily)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 116
Study: 26611240

Group type: EXPERIMENTAL
Intervention: Virtual reality game (Nintendo Wii) for cognitive enhancement, 10 sessions, 50 minutes/session, 2 days/week for 5 weeks
Number of subjects: 40
Study: 25618771

Group type: EXPERIMENTAL
Intervention: Interferential electrical stimulation + standard urotherapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard urotherapy only (control)
Number of subjects: 54
Study: 23408464

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Delayed Intervention (DI)
Number of subjects: 189
Study: 19820280

Group type: EXPERIMENTAL
Intervention: Portion-controlled diet (NutriSystem D) (PCD)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE) program
Number of subjects: 69
Study: 17377389

Group type: EXPERIMENTAL
Intervention: 0.1% retinaldehyde/6% glycolic acid cream (RALGA)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Vehicle cream (control)
Number of subjects: 145
Study: 14685749

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 121
Study: 11226797

Group type: EXPERIMENTAL
Intervention: Intrastromal corneal ring segments (ICRS) implantation
Number of subjects: 110
Study: 9507234

Group type: EXPERIMENTAL
Intervention: 4 g highly purified ethyl esters of eicosapentaenoic acid (EPA) (95% pure)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 4 g docosahexaenoic acid (DHA) (90% pure)
Number of subjects: 14
Study: 8028506

Group type: EXPERIMENTAL
Intervention: Exercise trial (2 hours of brisk walking at 30.9% ± 1.6% of VO2 max)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control trial (resting the day before the test meal)
Number of subjects: 12
Study: 2597658

Group type: EXPERIMENTAL
Intervention: Dexamethasone (intra-muscular)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 1254157

Group type: EXPERIMENTAL
Intervention: Post-operative prophylactic chemotherapy
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Endoxan)
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Radical operation during remission
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Continuous chemotherapy for at least 2 years
Number of subjects: 1022
Study: 31609644

Group type: EXPERIMENTAL
Intervention: Therapist Response Questionnaire for Adolescents (TRQ‐A)
Number of subjects: 192
Study: 30692875

Group type: EXPERIMENTAL
Intervention: High-Dose Remifentanil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-Dose Remifentanil
Number of subjects: 0
Study: 26427789

Group type: EXPERIMENTAL
Intervention: Topical Matricaria recutita L (chamomile) oil
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 26123824

Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 25 mg plus tramadol hydrochloride 75 mg
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 12.5 mg plus tramadol hydrochloride 37.5 mg
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 25 mg
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 75 mg
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 37.5 mg
Number of subjects: 606

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study: 23853029

Group type: EXPERIMENTAL
Intervention: AFQ056 200 mg daily
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: AFQ056 50 mg daily
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 21637908

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical device foam (ceramide-hyaluronic acid emollient)
Number of subjects: 0
Study: 18995935

Group type: EXPERIMENTAL
Intervention: Extended nasolabial flaps and coronoidectomy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Postoperative physiotherapy
Number of subjects: 47
Study: 17207303

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen 7.5/750 mg
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 15515415

Group type: EXPERIMENTAL
Intervention: 10 mg tropisetron
Number of subjects: 34

Group type: COMPARATOR
Intervention: 40 mg methylprednisolone
Number of subjects: 34
Study: 11556458

Group type: EXPERIMENTAL
Intervention: Topical ketorolac tromethamine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-treated eyes
Number of subjects: 19
Study: 9628270

Group type: EXPERIMENTAL
Intervention: Human insulin administered i.v. by continuous infusion for 7 days, followed by daily s.c. injections for 6 months. Intravenous insulin infusions were repeated every 12 months.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (untreated individuals).
Number of subjects: 14
Study: 7931953

Group type: EXPERIMENTAL
Intervention: Intratracheal bovine surfactant prophylaxis
Number of subjects: 64

Group type: COMPARATOR
Intervention: Air control
Number of subjects: 64
Study: 2904931

Group type: EXPERIMENTAL
Intervention: Azelastine 4.4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Azelastine 8.8 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Azelastine 17.6 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30597523

Group type: EXPERIMENTAL
Intervention: Weight reduction and IVF treatment (n = 160)
Number of subjects: 317

Group type: COMPARATOR
Intervention: IVF only (n = 157)
Number of subjects: 317
Study: 28024165

Group type: EXPERIMENTAL
Intervention: Etch-and-rinse adhesive
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Multimode universal adhesive
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Self-etch adhesive
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Conventional acid etching
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study: 26432647

Group type: EXPERIMENTAL
Intervention: remedē System therapy initiated at 1 month after implantation
Number of subjects: 173

Group type: COMPARATOR
Intervention: Inactive remedē System for 6 months (control)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: remedē System therapy
Number of subjects: 173

Group type: COMPARATOR
Intervention: Inactive remedē System (control)
Number of subjects: 173
Study: 23354337

Group type: EXPERIMENTAL
Intervention: Lightwand
Number of subjects: 3

Group type: COMPARATOR
Intervention: Intubating LMA
Number of subjects: 3

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 3
Study: 21071527

Group type: EXPERIMENTAL
Intervention: Nasal cannula with continuous flow at 2 L/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nasal cannula with oxygen-conserving device at 2 L/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nasal cannula with portable oxygen concentrator at 2 L/min
Number of subjects: 16
Study: 19864035

Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE) with zinostatin stimalamer and gelatin sponge
Number of subjects: 161

Group type: COMPARATOR
Intervention: Transarterial infusion chemotherapy (TAI) with zinostatin stimalamer
Number of subjects: 161
Study: 16887301

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15293609

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 11824325

Group type: EXPERIMENTAL
Intervention: Combined radio-chemotherapy (cisplatin 75 mg/m2 d1, etoposide 120 mg/m2 d1-3, Ifosfamid 1.5 mg/m2 d1-4, 3 cycles)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Radiotherapy (5 x 2 Gy/50 Gy)
Number of subjects: 58
Study: 9734346

Group type: EXPERIMENTAL
Intervention: Wheeze with bronchial hyperreactivity
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Preventive measures for progression from asymptomatic BHR to asthma
Number of subjects: 252
Study: 7818058

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiopentone 4 mg.kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg.kg‐1
Number of subjects: 30
Study: 2466389

Group type: EXPERIMENTAL
Intervention: Clonidine 4.5 micrograms kg‐1 orally 2 hours before operation (Group I)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Clonidine 4.5 micrograms kg‐1 orally 4 hours before operation (Group II)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Diazepam 0.15 mg kg‐1 orally 2 hours before operation (Group III)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo tablet 2 hours before operation (Group IV)
Number of subjects: 42
Study: 30332546

Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study: 29439691

Group type: EXPERIMENTAL
Intervention: Option Grid
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Picture Option Grid
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1100
Study: 26882102

Group type: EXPERIMENTAL
Intervention: Recombinant Human Interferon α1b therapy (rHuIFN‐α1b)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 24452659

Group type: EXPERIMENTAL
Intervention: Hyaluronidase 1500 IU (HYL)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal saline (NSL)
Number of subjects: 25
Study: 22889285

Group type: EXPERIMENTAL
Intervention: Diode laser as an adjunct to mechanical debridement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional mechanical debridement
Number of subjects: 30
Study: 19902489

Group type: EXPERIMENTAL
Intervention: 4-month buddy intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 17613792

Group type: EXPERIMENTAL
Intervention: Use of differential contextual information at test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normalized receiver operating characteristic data in terms of z-scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical indices suggested by Wixted and Stretch (2004)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-factor theory of remember-know and recognition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimisation of bias factors in remember-know methodology
Number of subjects: 0